Navigation Links
USPTO Grants Butamax a Further KARI Enzyme Patent
Date:7/17/2012

WILMINGTON, Del., July 17, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the biobutanol technology leader, today announced the United States Patent and Trademark Office (USPTO) has granted Butamax Patent Number 8,222,017 which protects a subset of key enzymes in the isobutanol production pathway.  

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

"We are pleased with the progress of our patent applications at the USPTO and this particular patent shows the expansion of our portfolio not just covering the fundamental pathway, but also protecting key pathway enzymes, far in advance of others in the field," commented Paul Beckwith, Butamax CEO, "This patent, and others like it soon to grant, demonstrates Butamax's strong innovation capability."

This latest patent issued from a series of applications covering a full-range of modified KARI enzymes. In this case, the enzyme subset is based on KARI enzymes having a modification that provides production efficiencies through the fundamental isobutanol biosynthetic pathway invented by Butamax. 

Butamax inventions include recombinant microorganisms that convert various feedstocks to biobutanol, process engineering for recovering biobutanol produced during fermentation, engineering design for optimized energy integrations, and various renewable fuel and chemical compositions. The depth and breadth of the portfolio reflects the synergy between Butamax's investors, BP and DuPont, as world class scientists and leaders in the biofuels industry. 

About Butamax

Butamax™ Advanced Biofuels, LLC, a joint venture between BP and DuPont was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact: Pam Schools  
910-777-7119  
pamela.schools@butamax.com

 


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
2. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
3. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
4. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
5. NSF CAREER grants support ocean energy, microforming, computer planning
6. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
7. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
8. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
9. Butamax™ Responds to Gevo Patent Infringement Lawsuit
10. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
11. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):